Outcomes following pacemaker implantation after transcatheter aortic valve implantation with CoreValve(®) devices: Results from the FRANCE 2 Registry

Gauthier Mouillet; Nicolas Lellouche; Masanori Yamamoto; Atsushi Oguri; Jean-Luc Dubois-Rande; Eric Van Belle; Martine Gilard; Marc Laskar; Emmanuel Teiger

doi:10.1002/ccd.25818

Outcomes following pacemaker implantation after transcatheter aortic valve implantation with CoreValve(®) devices: Results from the FRANCE 2 Registry

Catheter Cardiovasc Interv. 2015 Sep;86(3):E158-66. doi: 10.1002/ccd.25818. Epub 2015 Feb 18.

Authors

Gauthier Mouillet¹, Nicolas Lellouche¹, Masanori Yamamoto¹, Atsushi Oguri¹, Jean-Luc Dubois-Rande¹, Eric Van Belle², Martine Gilard³, Marc Laskar⁴, Emmanuel Teiger¹

Affiliations

¹ Cardiology Department, Hôpital Henri Mondor, Assistance Publique Hôpitaux De Paris & INSERM U 955, Creteil, France.
² Cardiology Department, Centre Hospitalier Universitaire De Lille, Lille, France.
³ Cardiology Department, Centre Hospitalier Universitaire De Brest, Hôpital De La Cavale Blanche, Brest, France.
⁴ Cardiac Surgery Unit, Centre Hospitalier Universitaire De Limoges, Cedex, France.

PMID: 25573445
DOI: 10.1002/ccd.25818

Abstract

Aims: Permanent pacemaker (PPM) implantation following high-degree atrioventricular block is frequently required after transcatheter aortic valve implantation (TAVI) using CoreValve(®) . Recent improvement of the delivery system (CoreValve Accutrak(®) ) aimed to ease delivery and reduce the PPM rate. Our study evaluated the incidences of PPM implantation following use of CoreValve(®) or CoreValve Accutrak(®) and the clinical outcome of these patients.

Methods and results: A total of 883 patients (82 ± 7 years; 41.3% female) with severe symptomatic aortic stenosis and self-expanding bioprosthesis implantation were included between January 2010 and October 2011 in 29 centers from the FRANCE 2 Registry. Follow-up data were available in 833 patients. CoreValve(®) and CoreValve Accutrak(®) were used in 343 (41.2%) and 490 (58.8%) patients, respectively. During a mean follow-up of 242 ± 179 days, all-cause mortality was similar in patients with versus without PPM implantation (16.3 vs. 16.9%, P = 0.832).There was no significant difference in the PPM incidence in CoreValve(®) and CoreValve Accutrak(®) patients (30.4% vs. 27.5%, P = 0.846).

Conclusion: PPM implantation remained frequent after TAVI using CoreValve Accutrak(®) . All-cause mortality was similar in patients with or without PPM implantation. The new device failed to show a significant decrease in PPM implantation incidence after TAVI. © 2015 Wiley Periodicals, Inc.

Keywords: aortic valve stenosis; pacemaker; transcatheter aortic valve implantation.

Publication types

Case Reports

MeSH terms

Aged
Aged, 80 and over
Comorbidity
Female
Humans
Male
Pacemaker, Artificial*
Transcatheter Aortic Valve Replacement / instrumentation*
Treatment Outcome